Globally more than 2 million people suffer from Crohn’s Disease – a debilitating auto-immune disorder characterized by chronic, and sometimes life-threatening, gut inflammation. Symptoms often include abdominal pain, cramping, diarrhea, nausea, vomiting, weight loss, rectal bleeding, ulcers, and a lack of energy. It’s estimated that each year Crohn’s Disease costs the global economy more than US$7.5b, with drawbacks to current treatments including serious side effects and daily administration.

 

Crohn’s disease is an auto-immune disorder whereby the patient’s immune system attacks itself. By interacting with a patient’s immune system to control the inflammatory response, products created using the StemSmart™ technology can moderate this immune attack, and reset the immune system of Crohn’s sufferers. A 78% clinical response and 53% clinical remission were reported in a Phase II clinical trial to treat life-threatening (refractory) Crohn’s Disease. These patients received just a single, non-invasive treatment. A Phase III Blinded Placebo-Controlled Trial comprising of >100 patients is currently being planned and is expected. A Phase 1 Trial in fistulas in Crohn’s disease comprising of 10 Patients has received ethics approval and recruitment is expected to commence in May 2021 with final reporting May 2022.